GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "We are making steady progress as it relates to AD04. We have initiated new a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38323 ADIAL PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-3074668 State ...

GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office. This patent expands Adial's intellectual property protection and covers the combination of the Company's proprietary genetic diagno ...

Follow Invezz on Telegram , Twitter , and Google News for instant updates >Adial Pharmaceuticals Inc (NASDAQ: ADIL) is up 60% today following a promising update on its alcohol disorder drug.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.What it means for Adial Pharmaceuticals stock Copy link to section The $7.7 million company based out of Virginia, United States said its AD04 did well in a clinical trial of Alcohol Use Disorder (AUD) patients. Its l ...

Group 1 - Adial Pharmaceuticals' stock is experiencing a significant increase following positive peer-reviewed results for its Alcohol Use Disorder (AUD) treatment, AD04 [1] - The peer review published in the European Journal of Internal Medicine emphasizes the treatment's efficacy and safety, particularly for patients with a specific genetic background [1] - CEO Cary Claiborne highlighted the potential of AD04 to enable precision treatments for AUD, aiming to manage alcohol consumption and reduce liver damage [1] Group 2 - Heavy trading activity was noted, with over 75 million shares of ADIL stock changing hands, significantly surpassing the average daily trading volume of approximately 4 million shares [2] - As of Wednesday morning, ADIL stock rose by 59.3%, recovering its year-to-date losses [2]

GLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high compliance among patients administered AD04 (low-dose ondansetron), the Company's lead investigational new drug produ ...

Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business u ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38323 ADIAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 82-3074668 (State or Other Jurisdiction of Inco ...

Core Viewpoint - Adial Pharmaceuticals has entered into a definitive agreement for the immediate exercise of outstanding warrants, which will generate approximately $3.53 million in gross proceeds for the company [1][2]. Group 1: Financial Details - The company will exercise warrants to purchase up to 1,150,000 shares of common stock at an exercise price of $2.82 per share, originally issued in October 2023 [1]. - In exchange for the immediate exercise of the warrants, Adial will issue new unregistered warrants to purchase up to 2,300,000 shares of common stock, also at an exercise price of $2.82 per share, with an eighteen-month term [2]. - The offering is expected to close on or about March 6, 2024, subject to customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the exercise of the warrants will be used for general corporate purposes, including administrative expenses, working capital, and to support regulatory and clinical activities related to AD04, the company's lead investigational drug for Alcohol Use Disorder (AUD) [2]. Group 3: Company Overview - Adial Pharmaceuticals is focused on developing therapies for addiction and related disorders, with its lead product AD04 being a serotonin-3 receptor antagonist aimed at treating AUD in heavy drinking patients [5]. - The ONWARD™ pivotal Phase 3 clinical trial for AD04 showed promising results in reducing drinking among heavy drinking patients without significant safety concerns [5]. - AD04 is also believed to have potential applications in treating other addictive disorders, including Opioid Use Disorder, gambling, and obesity [5].

CHARLOTTESVILLE, Va., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,905,562 was issued on February 20, 2024 by the United States Patent and Trademark Office. The patent covers the Company's lead investigational new drug product, AD04, and its ability to target the ser ...